ARTICLE | Company News
Celyad gains on CAR T deal amendment
August 4, 2017 11:20 PM UTC
Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) amended a 2015 deal to increase its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC (Lebanon, N.H.) and Dartmouth College (Hanover, N.H.).
Celyad gained €2.97 (11%) to €31.37 in Brussels on Friday, and added $5.68 (18%) to $38.05 in New York...
BCIQ Target Profiles
Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)